AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 (Seite 25)
eröffnet am 21.03.17 23:52:12 von
neuester Beitrag 19.08.22 13:09:24 von
neuester Beitrag 19.08.22 13:09:24 von
Beiträge: 268
ID: 1.249.254
ID: 1.249.254
Aufrufe heute: 0
Gesamt: 60.613
Gesamt: 60.613
Aktive User: 0
ISIN: US05464T1043 · WKN: A2AA7B · Symbol: AXSM
71,17
USD
-2,61 %
-1,91 USD
Letzter Kurs 24.04.24 Nasdaq
Neuigkeiten
15.04.24 · globenewswire  |
10.04.24 · globenewswire |
01.04.24 · globenewswire |
25.03.24 · globenewswire |
25.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,0900 | +14,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,2400 | -9,59 | |
| 0,5058 | -12,79 | |
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Beitrag zu dieser Diskussion schreiben
Feedback
Die Presentation wurde vorgestern im vorfeld der Needham konferenz die am mittwoch stattfindet geupdated .Diese Biotechfirma ist wohl eines der günstigsten die ich je gesehen habe .
Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019.
Präsentation 31.März
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9N…
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Vice President, Clinical and Regulatory
Dr. Niecestro has served as our Head of Regulatory since October 2012. In addition, since 2004, Dr. Niecestro has served as a consultant to a variety of biopharmaceutical companies, including Keryx Biopharmaceuticals, Inc. and TG Therapeutics, Inc. Prior to 2004, Dr. Niecestro held numerous senior management positions including serving as Vice President of Clinical Development for Andrx Laboratories, Senior Director, Clinical Development and Therapeutic Head for Gastrointestinal, Oncology and Stroke at Eisai Inc., and Director, Clinical Operations and NDA Planning for Organon Inc. While at Andrx, Dr. Niecestro was part of the team that developed the following approved drugs: extended-release metformin, extended-release lovastatin, and valproic acid. At Eisai, Dr. Niecestro played a pivotal role in the development and commercialization of Aciphex (rabeprazole sodium) and the post-NDA program for Aricept (donepezil sodium), and was involved in the launch of both the oncology and neurology franchises in the United States. While at Organon Dr. Niecestro was part of the team that developed and commercialized the following drugs: Zemuron (rocuronium bromide), Orgaran (danaparoid sodium), Humegon (FSH/LH), Follistim (recombinant FSH beta), and Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol). Dr. Niecestro has been involved in the filing of over 45 INDs, has over 60 peer-reviewed publications, and holds 3 patents. Dr. Niecestro completed his graduate and post-graduate work at the University of Illinois at Chicago.
Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019.
Präsentation 31.März
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9N…
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Vice President, Clinical and Regulatory
Dr. Niecestro has served as our Head of Regulatory since October 2012. In addition, since 2004, Dr. Niecestro has served as a consultant to a variety of biopharmaceutical companies, including Keryx Biopharmaceuticals, Inc. and TG Therapeutics, Inc. Prior to 2004, Dr. Niecestro held numerous senior management positions including serving as Vice President of Clinical Development for Andrx Laboratories, Senior Director, Clinical Development and Therapeutic Head for Gastrointestinal, Oncology and Stroke at Eisai Inc., and Director, Clinical Operations and NDA Planning for Organon Inc. While at Andrx, Dr. Niecestro was part of the team that developed the following approved drugs: extended-release metformin, extended-release lovastatin, and valproic acid. At Eisai, Dr. Niecestro played a pivotal role in the development and commercialization of Aciphex (rabeprazole sodium) and the post-NDA program for Aricept (donepezil sodium), and was involved in the launch of both the oncology and neurology franchises in the United States. While at Organon Dr. Niecestro was part of the team that developed and commercialized the following drugs: Zemuron (rocuronium bromide), Orgaran (danaparoid sodium), Humegon (FSH/LH), Follistim (recombinant FSH beta), and Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol). Dr. Niecestro has been involved in the filing of over 45 INDs, has over 60 peer-reviewed publications, and holds 3 patents. Dr. Niecestro completed his graduate and post-graduate work at the University of Illinois at Chicago.
In den letzten Minuten wurde die Aktie unter die $4 Marke gedrückt vermutlich short covering .Nachbörslich ist AXSM zumindest aktuell wieder bei $4.20 die Aktie ist sowieso viel zu günstig als das sie lange unter $4 bleiben könnte außerdem rücken die Phase 3 Daten immer näher .Auch ist die Aktie ein sehr attraktiver Übernahmekandidat bei der breiten Pipeline und super niedrigen bewertung .Ok das wars bis nächste Woche .
http://www.nasdaq.com/de/symbol/axsm/after-hours
http://www.nasdaq.com/de/symbol/axsm/after-hours
die aktie scheint luft zu holen bevor der marathon weitergeht
Axsome Therapeutics Inc (AXSM) Given a $13.00 Price Target by Cantor Fitzgerald Analysts
https://baseballnewssource.com/markets/axsome-therapeutics-i…
Antwort auf Beitrag Nr.: 54.644.543 von Aurum2010 am 30.03.17 15:04:37
schön von dir zu lesen Aurum
Zitat von Aurum2010:Zitat von 2brix: Danke fürs posten Biohero!
Kannst dich hier Anmelden, dann bekommste diese Infos umgehend
http://phx.corporate-ir.net/phoenix.zhtml?c=254022&p=irol-al…
schön von dir zu lesen Aurum
Trading Spotlight
Im titel steht 4 Phase 3 Studien eigentlich sind es bald soar 5 Phase3 studien nachdem jetzt das kapital beschafft worden ist . Ich kenne kein weiteres Biotech mit 5 Phase 3 Studien für $100 Million eigentlich nur $45 Million wenn man Cash dazu rechnet also schon sehr sehr attraktiv .
Marktkap: $95 Million
Cash: $50 Million
Kurs: 4.17
http://biopharmcatalyst.com/companies/company-pipeline-datab…
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3
Phase 3 initiation contingent upon resources.
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3
Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
Marktkap: $95 Million
Cash: $50 Million
Kurs: 4.17
http://biopharmcatalyst.com/companies/company-pipeline-datab…
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3
Phase 3 initiation contingent upon resources.
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3
Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
Antwort auf Beitrag Nr.: 54.637.610 von 2brix am 29.03.17 17:40:11
Kannst dich hier Anmelden, dann bekommste diese Infos umgehend
http://phx.corporate-ir.net/phoenix.zhtml?c=254022&p=irol-al…
Zitat von 2brix: Danke fürs posten Biohero!
Kannst dich hier Anmelden, dann bekommste diese Infos umgehend
http://phx.corporate-ir.net/phoenix.zhtml?c=254022&p=irol-al…
Ich hab eben Biorunup und Bionap angeschrieben vielleicht bringen sie einen artikel über AXSM raus sie haben immerhin einige follower das könnte für zusätzlich push sorgen .
Danke fürs posten Biohero!
Vielleicht sehen wir diese Woche noch die $5 ...
Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares ..
https://globenewswire.com/news-release/2017/03/29/946291/0/e…
Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares ..
https://globenewswire.com/news-release/2017/03/29/946291/0/e…
Durchsuchen
AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017
